Bicycle Therapeutics plc (NASDAQ:BCYC) Sees Significant Growth in Short Interest

Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 3,940,000 shares, a growth of 14.9% from the December 15th total of 3,430,000 shares. Based on an average daily volume of 591,800 shares, the days-to-cover ratio is currently 6.7 days.

Insider Transactions at Bicycle Therapeutics

In related news, Director Bros. Advisors Lp Baker purchased 985,397 shares of the business's stock in a transaction on Friday, December 13th. The shares were acquired at an average price of $13.76 per share, for a total transaction of $13,559,062.72. Following the purchase, the director now owns 9,537,643 shares of the company's stock, valued at $131,237,967.68. This trade represents a 11.52 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin Lee sold 9,038 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares in the company, valued at $6,974,916.34. This trade represents a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,933 shares of company stock valued at $549,501 in the last quarter. 8.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors have recently made changes to their positions in BCYC. Armistice Capital LLC lifted its holdings in Bicycle Therapeutics by 17.9% in the 2nd quarter. Armistice Capital LLC now owns 1,972,000 shares of the company's stock valued at $39,913,000 after purchasing an additional 300,000 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in shares of Bicycle Therapeutics by 21.5% in the third quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company's stock worth $41,887,000 after buying an additional 327,089 shares in the last quarter. First Light Asset Management LLC boosted its position in Bicycle Therapeutics by 16.1% during the second quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company's stock worth $28,028,000 after acquiring an additional 191,717 shares during the last quarter. Point72 Asset Management L.P. grew its stake in Bicycle Therapeutics by 1,438.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company's stock valued at $20,362,000 after acquiring an additional 841,299 shares in the last quarter. Finally, Avoro Capital Advisors LLC purchased a new stake in Bicycle Therapeutics during the 2nd quarter valued at about $14,168,000. 86.15% of the stock is owned by institutional investors and hedge funds.

Bicycle Therapeutics Stock Down 1.8 %

Shares of BCYC stock traded down $0.25 during trading hours on Friday, hitting $13.34. 203,978 shares of the company's stock were exchanged, compared to its average volume of 814,647. Bicycle Therapeutics has a fifty-two week low of $12.17 and a fifty-two week high of $28.67. The firm has a market cap of $921.13 million, a P/E ratio of -4.05 and a beta of 0.92. The firm has a 50 day moving average of $17.54 and a two-hundred day moving average of $21.46.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, topping analysts' consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million during the quarter, compared to analysts' expectations of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm's revenue for the quarter was down 50.0% on a year-over-year basis. During the same period in the prior year, the business posted ($1.26) earnings per share. On average, equities analysts forecast that Bicycle Therapeutics will post -3.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Needham & Company LLC reiterated a "buy" rating and set a $32.00 price objective on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Stephens assumed coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They issued an "equal weight" rating and a $25.00 target price on the stock. B. Riley dropped their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $34.50.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.